-
Company News for May 28, 2010 - Corporate Summary
Friday, May 28, 2010 - 9:42am | 205• Royal Dutch Shell (NYSE:RDSA) announced that it agreed to buy privately held East Resources for $4.7 billion in cash to increase its shale gas exposure in North America • Prudential (NYSE:PRU) is reportedly trying to renegotiate its previous $35.5 bid for AIG's (NYSE:AIG) Asian AIA unit, as major...
-
Zacks’ Voice Of The People Highlights Opportunities With Goldman (GS) And SPDR S&P 500 ETF (SPY)
Thursday, May 27, 2010 - 6:08pm | 285Yesterday’s washout was the kind of trading action typically seen at the bottom of a correction. We gapped down hard in the morning, but instead of watching investors panic and sell into the(...)Read the rest of Zacks’ Voice Of The People Highlights Opportunities With Goldman (GS) And SPDR S&P...
-
Short-Term Buy Signal for Goldman Sachs (GS)
Thursday, May 27, 2010 - 4:07pm | 175Shares of Goldman Sachs (NYSE: GS) are higher on the session by 3.46%, currently trading $144.79. The stock has been quite volatile as of late, with both bulls and bears coming to play in the name recently. Taking a look the technicals, the stock is exhibiting a short term-buy signal. Take a look...
-
Cramer's Stop Trading!: Buy Citi Stock (C, GS)
Thursday, May 27, 2010 - 3:51pm | 117NEW YORK (TheStreet) -- On his Thursday Stop Trading! segment on CNBC, Jim Cramer urged investors to buy Citi(NYSE: C) stock and own it for the next two years. Citi chief Vikram Pandit has done "an amazing job," in Cramer's opinion. Cramer said it's not too late to buy shares in Citi and urges...
-
J.P. Morgan Retains "Neutral" Rating On Biogen Idec (BIIB)
Thursday, May 27, 2010 - 2:47pm | 117In a research report released by J.P. Morgan (NYSE: JPM), the firm reiterated their Neutral rating on shares of Biogen Idec (NASDAQ: BIIB). JPM has a price target of $55.00 on the stock. During the current trading session, BIIB shares have gained 1.18% to $47.92. Biogen Idec Inc. (BIIB) is a...
-
Benzinga's Daily Reading List
Thursday, May 27, 2010 - 12:38pm | 243Here's a look at what Benzinga's reading today. Benzinga's Daily Reading List Feeling bad about your bankruptcy? Well, so did Thomas Jefferson and Abraham Lincoln. Don't tell Goldman Sachs (NYSE: GS). It only took 6 million gallons of oil for the Obama administration to realize that offshore...
-
Mid-Day Market Movers (FSII, SAPX, PERF, RODM)
Thursday, May 27, 2010 - 11:30am | 143FSI International Inc (NASDAQ: FSII) climbed 34.18% to $3.69 by 11:09 am. FSII raised its Q3 revenue forecast beyond the Wall Street expectations. Seven Arts Pictures PLC (NASDAQ: SAPX) shares advanced 24.80% to $1.46. Although SAPX lost 78.73% over the past 52 weeks, the S&P 500 has gained 19....
-
Company News for May 27, 2010 - Corporate Summary
Thursday, May 27, 2010 - 9:48am | 176• Tiffany (NYSE:TIF) reported first quarter earnings of 50 cents, versus Zacks projections of 36 cents, on a 22.4% revenue gain to $633.6 million, which beat projections of $609 million • Heinz (NYSE:HNZ) beat fiscal fourth quarter earnings by one penny, reporting at 60 cents per share on a 8.3%...
-
Today’s Best Market Rumors (5/27/2010)
Thursday, May 27, 2010 - 8:59am | 388Updated throughout the day. Goldman Sachs Group (NYSE: GS) wealth management customers are in danger of leaving the firm (Reuters) Sovereign debt issues outside Europe will pick up (CNBC) Sony Corp. (NYSE:SNE) may invest in future liquid-crystal-display panel production lines as part of its joint...
-
U.S. Treasury Reports that 1.5 Billion Share Sale Completed; Plans to Sell 1.5 Billion More
Wednesday, May 26, 2010 - 4:08pm | 154Dow Jones is reporting that The U.S. Treasury Department said it had received gross proceeds of about $6.2 billion from selling 1.5 billion in Citigroup Inc. shares (NYSE: C). The Treasury also plans to sell an additional 1.5 billion shares in the company. “Treasury, which took a 27% stake in...
-
Biogen Starts Patient Enrollment - Analyst Blog
Wednesday, May 26, 2010 - 3:42pm | 650Biogen Idec (BIIB) and Abbott (ABT) recently announced that they have started enrolling patients for their phase III study with daclizumab. The study– DECIDE, will evaluate the efficacy and safety of daclizumab in patients suffering from relapsing-remitting multiple sclerosis (RRMS). The candidate...
-
Focus Shifts Back to Domestic Issues 05-26-2010
Wednesday, May 26, 2010 - 2:53pm | 788Cusick’s Corner After the initial pop on the open, the market is holding onto these gains and there’s just whippy action into the Midday. As I noted yesterday, there’s irrational behavior in the market -- the VIX popped 50% in a few days, which even with all the monumental moves that we have had...
-
Goldman Sachs Raises AutoZone Price Target (AZO)
Wednesday, May 26, 2010 - 2:24pm | 139In a research report released by Goldman Sachs (NYSE: GS) today, the firm reiterated their Neutral rating on shares of AutoZone (NYSE: AZO), but gave the stock a big price target boost, from $160 to $198. Yesterday before the opening bell, AZO reported EPS of $4.12 compared to Wall Street...
-
Goldman Sachs Raises AutoZone Price Target (AZO)
Wednesday, May 26, 2010 - 2:24pm | 139In a research report released by Goldman Sachs (NYSE: GS) today, the firm reiterated their Neutral rating on shares of AutoZone (NYSE: AZO), but gave the stock a big price target boost, from $160 to $198. Yesterday before the opening bell, AZO reported EPS of $4.12 compared to Wall Street...
-
Goldman Sachs Lowers Price Targets On Managed Care Stocks (CI, UNH, HNT)
Wednesday, May 26, 2010 - 1:09pm | 128Goldman Sachs (NYSE: GS) said that they are lowering price targets on Managed Care stocks by 2%-15% in order to "adjust multiples to more realistic levels in light of recent market weakness and volatility." According to the report, however, the lowered targets still reflect 26% near-term upside....